NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-176-2022-0-CA-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease CA National Stage 3154761 Pending
NCI E-176-2022-0-CN-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease CN National Stage 202080065098.2 Pending
NCI E-176-2022-0-AU-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease AU National Stage 2020349353 Pending
NCI E-176-2022-0-BR-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease BR National Stage BR112022004861 Pending
NCI E-176-2022-0-JP-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease JP National Stage 2022-517823 Pending
NCI E-494-2013-0-AU-22 Methods of Preparing Anti-human Papillomavirus Antigen T Cells AU DIV 2020233702 Issued
NEI E-058-2018-0-US-03 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) For Use In Cell Therapy And Tissue Engineered Products US National Stage 16/981,531 11531844 Issued PDF
NEI E-058-2018-0-AU-04 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO
VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL
THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS 		AU National Stage 2019236297 Pending
NINDS E-025-2018-1-CH-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof CH EP 19716018.7 Issued
NINDS E-025-2018-1-GB-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof GB EP 19716018.7 Issued
NINDS E-025-2018-1-IE-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof IE EP 19716018.7 Issued
NINDS E-025-2018-1-EP-02 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof EP National Stage 19716018.7 Issued
NINDS E-025-2018-1-DE-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof DE EP 19716018.7 Issued
NINDS E-025-2018-1-FR-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof FR EP 19716018.7 Issued
NCI E-036-2018-0-KR-04 HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS KR National Stage 2020-7026443 Abandoned
NCI E-097-2018-0-SA-14 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES SA National Stage 520420134 Pending
NCI E-097-2018-0-AE-03 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES AE National Stage P6001291/2020 Pending
NHGRI E-122-2017-0-PCT-02 CANCER DETECTION AND CLASSIFICATION PCT PCT PCT/US2020/050522 Expired
NCI E-182-2019-2-PCT-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PCT PCT COMB PCT/US2020/050439 Expired
NCI E-182-2019-2-EP-05 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER EP National Stage 20785624.6 Pending
NCI E-097-2018-0-US-16 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES US National Stage 16/980,205 Pending
NEI E-227-2018-0-PCT-02 Druggable Taraget to Treat Retinal Degeneration PCT PCT PCT/US2020/050540 Expired
NEI E-227-2018-0-KR-11 Druggable Taraget to Treat Retinal Degeneration KR National Stage 10-2022-7012050 Pending
NCI E-182-2019-2-CA-03 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER CA National Stage 3153096 Pending
NCI E-494-2013-0-HK-21 Methods of Preparing Anti-human Papillomavirus Antigen T Cells HK EP 42020015851.7 Issued
NCI E-227-2006-5-AU-21 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS AU DIV 2020230283 Issued
NCI E-030-2022-0-PCT-02 Anti-Viral Compositions And Methods Of Making And Using PCT PCT PCT/US2020/050200 Expired
NCI E-097-2018-0-IN-10 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN National Stage 202047039152 Pending
NCI E-097-2018-0-MX-12 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES MX National Stage MX/a/2020/009472 Pending
NCATS E-229-2016-0-US-05 PEPTIDE INHIBITORS OF PHOSPHOGLYCERATE MUTASE AND METHODS OF USE US DIV 17/016,168 Abandoned
NCI E-097-2018-0-CN-06 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES CN National Stage 201980018105.0 Pending
NCI E-097-2018-0-CA-05 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES CA National Stage 3093567 Pending
NCI E-097-2018-0-SG-15 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES SG National Stage 11202008796V Pending
NCI E-097-2018-0-ZA-17 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES ZA National Stage 2020/05571 Pending
NCI E-097-2018-0-NZ-13 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES NZ National Stage 767782 Pending
NCI E-081-2018-0-US-03 17-BETA-HYDROXYWITHANOLIDES AND USE THEREOF IN TREATING CANCER US National Stage 16/978,442 Pending
NIDA E-023-2018-0-EP-03 DREADD ACTUATORS EP National Stage 19706192.2 Pending
NCI E-162-2014-0-US-09 Human Monoclonal Antibodies (mAbs) Against EphA4 As Candidate Therapeutics US CON 17/012,928 Abandoned
NINDS E-025-2018-1-US-03 POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF US National Stage 16/977,897 Pending
NHLBI E-218-2016-1-US-03 Immunogens, Compositions, And Methods For Treating Dyslipidemia US National Stage 16/977,648 Pending
NCI E-097-2018-0-AU-04 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES AU National Stage 2019235926 Pending
NCATS E-117-2018-0-US-03 2,6-DIMETHOXY-4-(5-PHENYL-4-THIOPHENE-2-YL-1H-IMIDAZOL-2-YL)-PHENOL (DPTIP) A SMALL MOLECULE INHIBITOR OF NEUTRAL SPHINGOMYELINASE 2 (nSMase-2) FOR THE TREATMENT OF
NEURODEGENERATIVE AND ONCOLOGIC DISEASES 		US National Stage 16/977,305 11766423 Issued PDF
NIAID E-089-2002-1-US-89 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 US DIV 17/009,448 11753627 Issued PDF
NCI E-097-2018-0-IL-09 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IL National Stage 277078 Pending
NIAID E-297-2016-2-US-07 VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES US DIV 17/008,025 Pending
NCATS E-084-2020-0-PCT-02 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators PCT PCT PCT/US2020/048482 Expired
NCATS E-084-2020-0-US-03 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF US National Stage 17/638,929 Pending
NIAID E-048-2020-0-PCT-02 COMPOSITIONS INCLUDING IGG Fe MUTATIONS AND USES THEREOF PCT PCT PCT/US2020/048253 Expired
NCATS E-253-2017-0-US-03 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME US National Stage 16/976,012 11649218 Issued PDF
NCI E-171-2018-9-US-06 MODIFIED CELLS AND METHODS OF THERAPY US CON 17/003,081 11583556 Issued PDF